| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 10-Q |
| 04 Nov 2026 | SCHEDULE 13D/A |
| 04 Nov 2026 |
Form 4: Saadi Ryan H., Director
Received 50,000,000 shares as a grant or award |
| 04 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 2, 2026, Susan Podlogar gave notice of her resignation from service as a director of Tevogen Inc. (the “Company”), effective immediately. In connection with Ms. Podlogar’s resignation, the Company’s Board of Directors (the “B... |
| 03 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
THIS FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”), dated as of October 27, 2026, between TEVOGEN INC. (formerly known as Tevogen Bio Holdings Inc.), a Delaware corporation, as borrower (“Borrower”) and The Patel Family, LLP, a De... |
| 30 Sep 2026 |
8-K: Other Events
Both previously disclosed Nasdaq compliance matters are now closed |
| 16 Sep 2026 | SCHEDULE 13D/A |
| 16 Sep 2026 | SCHEDULE 13D/A |
| 16 Sep 2026 |
Form 4: Saadi Ryan H., Director
Received 8,000,000 shares as a grant or award |
| 16 Sep 2026 |
Form 4: Desai Kirti, Chief Financial Officer
Received 750,000 shares as a grant or award |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Tevogen Inc., a Delaware corporation (the “Company”), hereby grants shares of the Company’s common stock, par value $0.0001 per share (the “Stock”), to the Grantee named below, subject to the vesting conditions set forth below (such gran... |
| 15 Sep 2026 |
Form 4: Goh Keow Lin, Director
Received 75,000 shares as a grant or award |
| 15 Sep 2026 |
Form 4: Podlogar Susan M, Director
Received 75,000 shares as a grant or award |
| 15 Sep 2026 |
Form 4: Sordillo Victor J., Director
Received 75,000 shares as a grant or award |
| 15 Sep 2026 |
Form 4: Feike Jeffrey L., Director
Received 75,000 shares as a grant or award |
| 15 Sep 2026 |
Form 4: Patton Curtis L., Director
Received 75,000 shares as a grant or award |
| 10 Sep 2026 |
8-K: Other Events
On September 9, 2026, Tevogen Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the $15 million minimum market value of publicly held share... |
| 26 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
THIS AMENDMENT NO. 2 (this “Amendment”) to the Tevogen Inc. 2024 Omnibus Incentive Plan (the “Plan”), which increases the number of shares available for issuance under the Plan by 100,000,000 shares, was adopted by the Board of Directors... |
| 24 Aug 2026 | S-8 |
| 14 Aug 2026 | 10-Q |
Loading...